Persistent effect of IFNAR-1 genetic polymorphism on the long-term pathogenesis of chronic HBV infection

Viral Immunology

Volumn 23, Issue 3, 2010, Pages 251-257

  He, Xing Xing ^a   Chang, Ying ^a   Jiang, Hua Jun ^a   Tang, Feng ^a   Meng, Fan Ying ^a   Xie, Qiong Hui ^a   Li, Pei Yuan ^a   Song, Yu Hu ^a   Lin, Ju Sheng ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON RECEPTOR; INTERFERON RECEPTOR 1; UNCLASSIFIED DRUG; ALPHA BETA INTERFERON RECEPTOR; IFNAR1 PROTEIN, HUMAN;

ADULT; AGED; ALLELE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS PATHOGENESIS; CASE CONTROL STUDY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; LIVER TUMOR; MIDDLE AGED;

HEPATITIS B VIRUS;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, INTERFERON ALPHA-BETA;

EID: 77954167914     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2009.0102     Document Type: Article

References (42)

1. Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107.
2. Szmaragd C, Nichols RA, and Balloux F: A novel approach to characterise pathogen candidate genetic polymorphisms involved in clinical outcome. Infect Genet Evol 2006;6:38-45.
3. Casanova JL, and Abel L: Human genetics of infectious diseases: a unified theory. EMBO J 2007;26:915-922.
4. Clementi M, and Di Gianantonio E: Genetic susceptibility to infectious diseases. Reprod Toxicol 2006;21:345-349.
5. Shi M, Fu J, Shi F, et al.: Transfusion of autologous cytokineinduced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection. Clin Immunol 2009;132: 43-54.
6. Pham TN, Mercer SE, and Michalak TI: Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles. J Viral Hepat 2009;16:547-556.
7. Gujar SA, and Michalak TI: Primary occult hepadnavirus infection induces virus-specific T-cell and aberrant cytokine responses in the absence of antiviral antibody reactivity in the woodchuck model of hepatitis B virus infection. J Virol 2009;83:3861-3876.
8. Le Bon A, and Tough DF: Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 2002;14:432-436.
9. Perry AK, Chen G, Zheng D, et al.: The host type I interferon response to viral and bacterial infections. Cell Res 2005;15: 407-422.
10. Platanias LC: Mechanisms of type-I- and type-II-interferonmediated signalling. Nat Rev Immunol 2005;5:375-386.
11. de Weerd NA, Samarajiwa SA, and Hertzog PJ: Type I interferon receptors: biochemistry and biological functions. J Biol Chem 2007;282:20053-20057.
12. Uze G, Lutfalla G, Eid P, et al.: Murine tumor cells expressing the gene for the human interferon alpha beta receptor elicit antibodies in syngeneic mice to the active form of the receptor. Eur J Immunol 1991;21:447-451.
13. Benoit P, Maguire D, Plavec I, et al.: A monoclonal antibody to recombinant human IFN-alpha receptor inhibits biologic activity of several species of human IFN-alpha, IFN-beta, and IFN-omega. Detection of heterogeneity of the cellular type I IFN receptor. J Immunol 1993;150:707-716.
14. Diop G, Hirtzig T, Do H, et al.: Exhaustive genotyping of the interferon alpha receptor 1 (IFNAR1) gene and association of an IFNAR1 protein variant with AIDS progression or susceptibility to HIV-1 infection in a French AIDS cohort. Biomed Pharmacother 2006;60:569-577.
15. Welzel TM, Morgan TR, Bonkovsky HL, et al.: Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral longterm treatment against cirrhosis trial. Hepatology 2009;49: 1847-1858.
16. Fortunato G, Calcagno G, Bresciamorra V, et al.: Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J Interferon Cytokine Res 2008;28:141-152.
17. Song Le H, Xuan NT, Toan NL, et al.: Association of two variants of the interferon-alpha receptor-1 gene with the presentation of hepatitis B virus infection. Eur Cytokine Netw 2008;19:204-210.
18. Zhou J, Lu L, Yuen MF, et al.: Polymorphisms of type I interferon receptor 1 promoter and their effects on chronic hepatitis B virus infection. J Hepatol 2007;46:198-205.
19. Leyva L, Fernandez O, Fedetz M, et al.: IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J Neuroimmunol 2005;163:165-171.
20. Sriram U, Barcellos LF, Villoslada P, et al.: Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes Immun 2003;4:147-152.
21. Tangwattanachuleeporn M, Sodsai P, Avihingsanon Y, et al.: Association of interferon-gamma gene polymorphism (+874A) with arthritis manifestation in SLE. Clin Rheumatol 2007;26:1921-1924.
22. Zhou J, Smith DK, Lu L, et al.: A non-synonymous single nucleotide polymorphism in IFNAR1 affects susceptibility to chronic hepatitis B virus infection. J Viral Hepat 2009;16: 45-52.
23. Zhang X, Deriaud E, Jiao X, et al.: Type I interferons protect neonates from acute inflammation through interleukin 10- producing B cells. J Exp Med 2007;204:1107-1118.
24. Inglefield JR, Dumitru CD, Alkan SS, et al.: TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN. J Interferon Cytokine Res 2008;28:253-263.
25. Currie AJ, van der Most RG, Broomfield SA, et al.: Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J Immunol 2008;180: 1535-1544.
26. Aucan C, Walley AJ, Hennig BJ, et al.: Interferon-alpha receptor-1 (IFNAR1) variants are associated with protection against cerebral malaria in the Gambia. Genes Immun 2003; 4:275-282.
27. Xu D, Fu J, Jin L, et al.: Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006;177:739-747.
28. Zeng Z, Guan L, An P, et al.: A population-based study to investigate host genetic factors associated with hepatitis B infection and pathogenesis in the Chinese population. BMC Infect Dis 2008;8:1.
29. Excoffier L, Laval G, and Balding D: Gametic phase estimation over large genomic regions using an adaptive window approach. Hum Genomics 2003;1:7-19.
30. Slatkin M, and Excoffier L: Testing for linkage disequilibrium in genotypic data using the expectation-maximization algorithm. Heredity 1996;76(Pt 4):377-383.
31. Yu D, Tan AH, Hu X, et al.: Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA. Nature 2007;450:299-303.
32. Storr M, Emmerdinger D, Diegelmann J, et al.: The role of fatty acid hydrolase gene variants in inflammatory bowel disease. Aliment Pharmacol Ther 2009;29:542-551.
33. Amre DK, Mack DR, Morgan K, et al.: Interleukin 10 (IL-10) gene variants and susceptibility for paediatric onset Crohn's disease. Aliment Pharmacol Ther 2009;29:1025-1031.
34. Suneetha PV, Sarin SK, Goyal A, et al.: Association between vitamin D receptor, CCR5, TNF-alpha and TNF-beta gene polymorphisms and HBV infection and severity of liver disease. J Hepatol 2006;44:856-863.
35. Deng G, Zhou G, Zhai Y, et al.: Association of estrogen receptor alpha polymorphisms with susceptibility to chronic hepatitis B virus infection. Hepatology 2004;40:318-326.
36. Yu MW, Pai CI, Yang SY, et al.: Role of N-acetyltransferase polymorphisms in hepatitis B related hepatocellular carcinoma: impact of smoking on risk. Gut 2000;47:703-709.
37. Thio CL, Mosbruger T, Astemborski J, et al.: Mannose binding lectin genotypes influence recovery from hepatitis B virus infection. J Virol 2005;79:9192-9196.
38. Thio CL, Astemborski J, Bashirova A, et al.: Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence. J Virol 2007;81:441-445.
39. Ben-Ari Z, Mor E, Papo O, et al.: Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol 2003;98:144-150.
40. Miyazoe S, Hamasaki K, Nakata K, et al.: Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am J Gastroenterol 2002;97:2086-2092.
41. Migita K, Maeda Y, Abiru S, et al.: Polymorphisms of interleukin-1beta in Japanese patients with hepatitis B virus infection. J Hepatol 2007;46:381-386.
42. Ji J, Shi J, Budhu A, et al.: MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009; 361:1437-1447.